This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| TRANSVAC2 | |
|---|---|
| Name | TRANSVAC2 |
| Formation | 2012 |
| Purpose | Support vaccine development |
| Headquarters | European Union |
| Region served | Europe, global |
TRANSVAC2
TRANSVAC2 is a European infrastructure project supporting vaccine development by providing shared services, facilities, and expertise to academic, industrial, and public health actors. It connects research institutions, biotechnology companies, regulatory bodies, and funding agencies to accelerate preclinical and early clinical vaccine candidates across infectious diseases, immunology, and public health emergencies. The initiative operates within networks of translational research platforms, fostering collaboration among well-known institutes and agencies.
TRANSVAC2 coordinates and delivers services through networks including European Commission-funded projects, Innovative Medicines Initiative, and research infrastructures such as European Organisation for Research and Treatment of Cancer and European Molecular Biology Laboratory. It links technology platforms at institutions like Institut Pasteur, Karolinska Institutet, CERN spin-offs, and Francis Crick Institute, offering assays, adjuvant characterisation, and immunology expertise. Stakeholders include biotechnology firms, pharmaceutical companies like GlaxoSmithKline, Sanofi, and Pfizer, as well as public health bodies such as European Centre for Disease Prevention and Control and World Health Organization. The network complements efforts by consortia including Coalition for Epidemic Preparedness Innovations and European Vaccine Initiative.
The project emerged from European research policy discussions involving Horizon 2020, Framework Programme 7, and recommendations by the European Strategy Forum on Research Infrastructures. Early consortium partners included Institut Pasteur, Vaccine Research Center (NIH), Imperial College London, University of Oxford, and Max Planck Society. Milestones involved establishing quality-controlled assay repositories with input from European Medicines Agency and coordinating translational pipelines used during outbreaks involving Ebola virus epidemic and Zika virus epidemic. TRANSVAC2 built on prior initiatives linked to Wellcome Trust, Gates Foundation, and national research councils such as Medical Research Council (UK) and Agence Nationale de la Recherche.
Governance incorporates representatives from academic partners like University College London, Karolinska Institutet, and University of Cambridge alongside industry partners such as AstraZeneca and Baxter International. Administrative oversight interacts with European Commission Directorates and advisory boards drawing experts from European Medicines Agency, US Food and Drug Administration, and WHO advisory groups. Project management used frameworks similar to European Research Council grants and collaborates with infrastructures including European Infrastructure for Translational Medicine and ELIXIR. Ethics and compliance engage national regulators like Agence Nationale de Sécurité du Médicament and institutional review boards from universities.
Services span assay development, GMP-like production, preclinical models, adjuvant evaluation, and immunogenicity testing performed in laboratories at partners such as Institut Pasteur, Pasteur Institute Network, Karolinska University Hospital, and University of Oxford Clinical Research Unit. Support includes antigen design using platforms from EMBL-EBI, bioinformatics pipelines aligned with CERN computing models, and systems immunology collaborations with Francis Crick Institute. Training programs mirror offerings from European School of Oncology and Wellcome Sanger Institute training courses. Quality assurance follows guidance from International Council for Harmonisation and regulatory science input from European Medicines Agency.
TRANSVAC2 partners include academic institutions like University of Bonn, University of Helsinki, ETH Zurich, and industry actors such as BioNTech, Moderna, and Novartis. Collaborations with public health and research funders include European Investment Bank, European Research Area, Wellcome Trust, and Bill & Melinda Gates Foundation. It engages with consortia such as Human Vaccines Project, European Vaccine Initiative, and networks including Global Fund stakeholders and Gavi, the Vaccine Alliance. Clinical trial coordination linked partners like ClinicalTrials.gov registries and national agencies including Public Health England and Robert Koch Institute.
Outputs include validated immunoassays, adjuvant characterisation data, and standardized preclinical models contributed to programs addressing Influenza pandemic, COVID-19 pandemic, Ebola virus epidemic, and Zika virus epidemic. TRANSVAC2-supported candidates progressed into trials at sites affiliated with Karolinska University Hospital, Oxford Vaccine Group, and National Institute for Biological Standards and Control. Publications involved collaborations with journals and institutions such as Nature, The Lancet, Science, Cell, and repositories linked to EMBL-EBI and PubMed Central. The project influenced policy dialogues involving European Commission health research priorities and coordinated responses with World Health Organization emergency frameworks.
Funding drew from Horizon 2020 and partner contributions from national agencies including Fonds National de la Recherche Scientifique and Deutsche Forschungsgemeinschaft, plus in-kind support from industry partners like GlaxoSmithKline and AstraZeneca. Sustainability strategies involve integration with infrastructures such as ELIXIR and seeking follow-on support from Horizon Europe and philanthropic funders like Wellcome Trust and Bill & Melinda Gates Foundation. Business models reference practices used by Innovative Medicines Initiative and public–private partnerships exemplified by Coalition for Epidemic Preparedness Innovations.
Category:Vaccine research